Roflumilast

Potent and selective phosphodiesterase (PDE4) inhibitor, IC50=0.7, 0.9, 0.7, 0.2 nM for PDE4A1, PDE4A4, PDE4B1 and PDE4B2 respectively1. Clinically useful agent for treatment of COPD2. Improves sensory gating in humans3 and improves memory in rodent models4. Mimics calorie restriction effects via activation of AMPK/SIRT1 and protects against diabetic nephropathy5. Reduces weight gain by increasing energy expenditure and improves glucose metabolism in mice6.